• Mucociliary ClearanceCompleted with Results

  Phase 3 study of inhaled mannitol in adults with cystic fibrosis , protocol number Pharmaxis DPM-CF-303

  This study evaluated the safety and effectiveness of the inhaled drug, Bronchitol® (mannitol).

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    5

  • Length of Participation:

    6 months

• Mucociliary ClearanceCompleted with Results

  Inhaled Dry Powder Mannitol in Cystic Fibrosis , protocol number Pharmaxis DPM-CF-302

  This Phase 3 study looked at the safety and effectiveness of treatment with inhaled dry powder mannitol.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30 to 89%

  • Number of Visits:

    7

  • Length of Participation:

    52 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.